Last reviewed 2026-04-20 · How we verify

Anti-OX40 antibody administration

Providence Health & Services · Phase 1 active Small molecule Quality 15/100

Anti-OX40 antibody administration is a Small molecule drug developed by Providence Health & Services. It is currently in Phase 1 development. Also known as: MEDI6469.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Anti-OX40 antibody administration
Also known as	MEDI6469
Sponsor	Providence Health & Services
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Dermatitis atopic
NASOPHARYNGITIS
Nasopharyngitis
DERMATITIS ATOPIC
Pyrexia
COVID-19
Influenza
BLOOD CREATINE PHOSPHOKINASE INCREASED
HEADACHE
Headache
Cough
Aphthous ulcer

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Anti-OX40 antibody administration CI brief — competitive landscape report
Anti-OX40 antibody administration updates RSS · CI watch RSS
Providence Health & Services portfolio CI

Frequently asked questions about Anti-OX40 antibody administration

What is Anti-OX40 antibody administration?

Anti-OX40 antibody administration is a Small molecule drug developed by Providence Health & Services.

Who makes Anti-OX40 antibody administration?

Anti-OX40 antibody administration is developed by Providence Health & Services (see full Providence Health & Services pipeline at /company/providence-health-services).

Is Anti-OX40 antibody administration also known as anything else?

Anti-OX40 antibody administration is also known as MEDI6469.

What development phase is Anti-OX40 antibody administration in?

Anti-OX40 antibody administration is in Phase 1.

What are the side effects of Anti-OX40 antibody administration?

Common side effects of Anti-OX40 antibody administration include Dermatitis atopic, NASOPHARYNGITIS, Nasopharyngitis, DERMATITIS ATOPIC, Pyrexia, COVID-19.

Manufacturer: Providence Health & Services — full pipeline
Also known as: MEDI6469

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing